scispace - formally typeset
W

Wen-Cai Ye

Researcher at Jinan University

Publications -  551
Citations -  10678

Wen-Cai Ye is an academic researcher from Jinan University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 41, co-authored 485 publications receiving 7917 citations. Previous affiliations of Wen-Cai Ye include Chinese Ministry of Education & Second Military Medical University.

Papers
More filters
Journal ArticleDOI

Design and Synthesis of Dimeric Securinine Analogues with Neuritogenic Activities.

TL;DR: A series of novel dimeric securinine analogues are identified as potent neurite outgrowth enhancers and may provide insights on drug discovery of neural repair and regeneration.
Journal ArticleDOI

Two new dimeric secoiridoid glycosides from the fruits of Ligustrum lucidum.

TL;DR: Two new secoiridoid glycosides, ligusides A and B (1 and 2), as well as seven known compounds, were isolated from the fruits of Ligustrum lucidum and their structures were elucidated on the basis of spectroscopic and chemical analysis.
Journal ArticleDOI

Myrtucomvalones A–C, three unusual triketone–sesquiterpene adducts from the leaves of Myrtus communis ‘Variegata’

TL;DR: In this paper, three triketone-sesquiterpene adducts, myrtucomvalones A-C (1, 3), along with four known compounds (4, 7) were isolated from the leaves of Myrtus communis ‘Variegata’.
Journal Article

Monomeric indole alkaloids from the aerial parts of Catharanthus roseus

TL;DR: A new alkaloid together with five known compounds were isolated and identified as vindolinine B (1), lochnericine (2), horhammericine (3), vindorosine (4), vindoline (5), and coronaridine (6).
Journal ArticleDOI

Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs

TL;DR: In this article, the authors demonstrated that tumour perivascular cells mediate tumour revascularization after withdrawal of AA-TKI therapy, and showed that combination therapy of regorafenib with the Axl inhibitor improves overall survival in mice metastatic CRC model by inhibiting tumour growth.